Table 4.
Incidence of treatment-emergent adverse events reported by ≥5% of patients assessed using UKU Scale.
| Adverse Events |
Risperidone
(n=21) n (%) |
Aripiprazole
(n=13) n (%) |
|---|---|---|
| Asthenia * | 11(45.9) | 0 |
| Sedation | 7(29.2) | 1(7.7) |
| Falling memory | 2(8.3) | 0 |
| Increased duration of sleep | 6(25) | 1(7.7) |
| Reduced duration of sleep | 2(8.4) | 1(7.7) |
| Rigidity | 2(8.4) | 0 |
| Hypokinesia* | 9(37.5) | 0 |
| Hyperkinesias | 0 | 1(7.7) |
| Tremor | 4(16.7) | 0 |
| Akathisia | 1(4.2) | 1(7.7) |
| Accommodation disturbance | 2(8.4) | 0 |
| Increased salivation | 2(8.4) | 0 |
| Constipation | 1(4.2) | 1(7.7) |
| Orthostatic dizziness* | 4(16.7) | 0 |
| Rash | 2(8.4) | 0 |
| Diminished sexual desire* | 4(16.7) | 0 |
| Head ache | 4(16.7) | 1(7.7) |
*p≤0.05.